These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31452197)

  • 1. Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia?
    Mirgh S; Ahmed R; Agrawal N; Khushoo V; Garg A; Francis S; Tejwani N; Singh N; Bhurani D
    Br J Haematol; 2019 Oct; 187(2):e33-e35. PubMed ID: 31452197
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
    Cerrano M; Castella B; Lia G; Olivi M; Faraci DG; Butera S; Martella F; Scaldaferri M; Cattel F; Boccadoro M; Massaia M; Ferrero D; Bruno B; Giaccone L
    Br J Haematol; 2020 Oct; 191(1):e28-e32. PubMed ID: 32686081
    [No Abstract]   [Full Text] [Related]  

  • 3. An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.
    Bond J; Marchand T; Touzart A; Cieslak A; Trinquand A; Sutton L; Radford-Weiss I; Lhermitte L; Spicuglia S; Dombret H; Macintyre E; Ifrah N; Hamel JF; Asnafi V
    Haematologica; 2016 Jun; 101(6):732-40. PubMed ID: 26944475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab in T-cell acute lymphoblastic leukaemia: A case report and review of the literature.
    Ruhayel SD; Valvi S
    Pediatr Blood Cancer; 2021 May; 68(5):e28829. PubMed ID: 33245179
    [No Abstract]   [Full Text] [Related]  

  • 5. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?
    Bonda A; Punatar S; Gokarn A; Mohite A; Shanmugam K; Nayak L; Bopanna M; Cheriyalinkal Parambil B; Khattry N
    Bone Marrow Transplant; 2018 Nov; 53(11):1487-1489. PubMed ID: 29884853
    [No Abstract]   [Full Text] [Related]  

  • 6. Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Fulcher J; Berardi P; Christou G; Villeneuve PJA; Bredeson C; Sabloff M
    Leuk Lymphoma; 2021 Sep; 62(9):2295-2297. PubMed ID: 33749497
    [No Abstract]   [Full Text] [Related]  

  • 7. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very high frequencies of leukaemia-initiating cells in precursor T-acute lymphoblastic leukaemia may be obscured by cryopreservation.
    Greystoke BF; Huang X; Wilks DP; Atkinson S; Somervaille TC
    Br J Haematol; 2013 Nov; 163(4):538-41. PubMed ID: 23927465
    [No Abstract]   [Full Text] [Related]  

  • 9. [Daratumumab for the treatment of relapsed T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a case report].
    Wang X; Hu MM; Xiao JY; Lin ZH; Shi TT; Li XF; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jul; 45(7):698. PubMed ID: 39231777
    [No Abstract]   [Full Text] [Related]  

  • 10. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.
    Vogiatzi F; Winterberg D; Lenk L; Buchmann S; Cario G; Schrappe M; Peipp M; Richter-Pechanska P; Kulozik AE; Lentes J; Bergmann AK; Valerius T; Frielitz FS; Kellner C; Schewe DM
    Blood; 2019 Aug; 134(8):713-716. PubMed ID: 31311816
    [No Abstract]   [Full Text] [Related]  

  • 11. Terminal deoxynucleotidyl transferase (TdT) negative early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with spontaneous acute kidney injury.
    Kidoguchi K; Yokoo M; Umino A; Aoki S; Kimura S
    Ann Hematol; 2020 Apr; 99(4):885-886. PubMed ID: 32025838
    [No Abstract]   [Full Text] [Related]  

  • 12. Pseudohyperkalemia due to severe leukocytosis: case presentation.
    Claver-Belver N; Cano-Corres R; Miró-Cañís S; Berlanga-Escalera E
    Clin Chem Lab Med; 2016 Dec; 54(12):e365-e367. PubMed ID: 27269895
    [No Abstract]   [Full Text] [Related]  

  • 13. Case Study Interpretation--Houston: Case 3. Early T-cell precursor-acute lymphoblastic leukemia.
    Park S
    Cytometry B Clin Cytom; 2011; 80(4):261-3. PubMed ID: 21638770
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation.
    Chan TSY; Sim JPY; Kwong YL
    Ann Hematol; 2017 Sep; 96(9):1569-1572. PubMed ID: 28573313
    [No Abstract]   [Full Text] [Related]  

  • 15. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Khogeer H; Rahman H; Jain N; Angelova EA; Yang H; Quesada A; Ok CY; Sui D; Wei P; Al Fattani A; Pierce S; Loghavi S; Lamb A; Hu P; Thakral B; Kanagal-Shamanna R; Jorgensen JL; Jabbour EJ; Kantarjian HM; Medeiros LJ; Khoury JD
    Br J Haematol; 2019 Aug; 186(4):538-548. PubMed ID: 31115909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD33, not early precursor T-cell phenotype, is associated with adverse outcome in adult T-cell acute lymphoblastic leukaemia.
    Guo RJ; Bahmanyar M; Minden MD; Chang H
    Br J Haematol; 2016 Mar; 172(5):823-5. PubMed ID: 26123477
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring of minimal residual disease in early T-cell precursor acute lymphoblastic leukaemia by next-generation sequencing.
    Pan X; Nariai N; Fukuhara N; Saito S; Sato Y; Katsuoka F; Kojima K; Kuroki Y; Danjoh I; Saito R; Hasegawa S; Okitsu Y; Kondo A; Onishi Y; Nagami F; Kiyomoto H; Hozawa A; Fuse N; Nagasaki M; Shimizu R; Yasuda J; Harigae H; Yamamoto M
    Br J Haematol; 2017 Jan; 176(2):318-321. PubMed ID: 26822323
    [No Abstract]   [Full Text] [Related]  

  • 18. Type B lactic acidosis due to Warburg effect in a child presenting with T cell acute lymphoblastic leukaemia: a milder phenotype.
    Khera S; Pramanik SK; Kalra S; Dwivedi A
    BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32188616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia.
    Ganzel C; Kharit M; Duksin C; Rowe JM
    Haematologica; 2018 Oct; 103(10):e489-e490. PubMed ID: 29954929
    [No Abstract]   [Full Text] [Related]  

  • 20. Pseudohyperkalaemia with acute leukaemia: association with pneumatic tube transport of blood specimens.
    Ku AS; Chen RH; Law RL
    Hong Kong Med J; 2014 Apr; 20(2):158-60. PubMed ID: 24714171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.